1230. Epidemiology and Risk Factors for Recurrent Invasive Methicillin-Resistant Staphylococcus aureus Infection — 9 U.S. States, 2006–2013
Session: Poster Abstract Session: Healthcare Epidemiology: MSSA, MRSA and Other Gram Positive Infections
Friday, October 5, 2018
Room: S Poster Hall

Background: Methicillin-resistant Staphylococcus aureus (MRSA) causes >70,000 invasive infections annually in the U.S., and recurrent infections pose a major clinical challenge. We examined risk factors for recurrent MRSA infections.

Methods: We identified patients with an initial invasive MRSA infection (isolation from a normally sterile body site) from 2006–2013, through active, population-based surveillance in selected counties in nine states through the Emerging Infections Program. Recurrence was defined as invasive MRSA isolation >30 days after initial isolation. We used logistic regression with backwards selection to evaluate adjusted odds ratios (aOR) associated with recurrence within 180 days, prior healthcare exposures, and initial infection type, controlling for patient demographics and comorbidities.

Results: Among 24,478 patients with invasive MRSA, 3,976 (16%) experienced a recurrence, including 61% (2,438) within 180 days. Risk factors for recurrence were: injection drug use (IDU) (aOR; 1.38, 95% confidence interval [CI]: 1.15–1.65), central venous catheters (aOR; 1.35, 95% CI: 1.22–1.51), dialysis (aOR; 2.00, 95% CI: 1.74–2.31), and history of MRSA colonization (aOR; 1.35, 95% CI: 1.22–1.51) (Figure). Recurrence was more likely for bloodstream infections (BSI) without another infection (aOR; 2.08, 95% CI: 1.74–2.48), endocarditis (aOR; 1.46, 95% CI: 1.16–1.55), and bone/joint infections (aOR; 1.38, 95% CI: 1.20–1.59), and less likely for pneumonia (aOR: 0.75, 95% CI: 0.64–0.89), compared to other initial infection types. When assessed separately, the presence of a secondary BSI with another infection increased the odds of recurrence over that infection without a BSI (aOR: 1.96, 95% CI: 1.68–2.30).

Conclusion: Approximately one in six persons with invasive MRSA infection had recurrence. We identified potential opportunities to prevent recurrence through infection control (e.g., management and early removal of central catheters). Other possible areas for preventing recurrence include improving the management of patients with BSI and bone/joint infections (including both during and after antibiotic treatment) and mitigating risk of infection from IDU.

 

Ian Kracalik, PhD, MPH1, Kelly Jackson, MPH1, Joelle Nadle, MPH2, Wendy Bamberg, MD3, Susan Petit, MPH4, Susan M. Ray, MD5, Ruth Lynfield, MD, FIDSA6, Lee H. Harrison, MD7, John M. Townes, MD8, Ghinwa Dumyati, MD, FSHEA9, William Schaffner, MD, FIDSA, FSHEA10, Jason Lake, MD11 and Isaac See, MD1, (1)Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, (2)California Emerging Infections Program, Oakland, CA, (3)Colorado Department of Public Health and Environment, Denver, CO, (4)Connecticut Department of Public Health, New Haven, CT, (5)Emory University School of Medicine, Atlanta, GA, (6)Minnesota Department of Health, St. Paul, MN, (7)University of Pittsburgh, Pittsburgh, PA, (8)Infectious Diseases, Oregon Health and Science University, Portland, OR, (9)NY Emerging Infections Program, Center for Community Health and Prevention, University of Rochester Medical Center, Rochester, NY, (10)Vanderbilt University School of Medicine, Nashville, TN, (11)Centers For Disease Control and Prevention, Atlanta, GA

Disclosures:

I. Kracalik, None

K. Jackson, None

J. Nadle, None

W. Bamberg, None

S. Petit, None

S. M. Ray, None

R. Lynfield, None

L. H. Harrison, None

J. M. Townes, None

G. Dumyati, None

W. Schaffner, None

J. Lake, None

I. See, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.